Thetis CEO, Gary Mathias, presents on Non-immunosuppressive Therapies for Gastrointestinal Diseases
BRANFORD, CT – (February 17, 2020) – Thetis Pharmaceuticals, a biopharmaceutical company developing non-immunosuppressive lipid therapies for treatment of gastrointestinal (GI) diseases, announced that its CEO, Gary Mathias, will present at NobleCon16 – Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida today, February 17th, 2020 at 1:00 pm Eastern Standard Time.
A high-definition, video webcast of the presentation is available at the following link: https://noble.mediasite.com/Mediasite/Play/e5f85da97b2641d6a1c5927c04a998e81d
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company developing first-in-class lipid therapies for treatment of gastrointestinal (GI) diseases. Lipid molecules play key roles in many aspects of biology, including metabolism, inflammation, immunological signaling and tissue repair. Thetis’ proprietary HEALER™ technology platform enables the development of bioactive lipids as patent-protected new molecular entities with enhanced bioavailability, efficacy, and stability, overcoming key hurdles that have historically limited their development as pharmaceutical drugs. Thetis is leveraging this technology to develop a de-risked pipeline of oral, non-immunosuppressive, small molecule therapies for treatment of GI disorders, including inflammatory bowel disease (IBD) and non-alcoholic steatohepatitis (NASH).